Impact of insulin-like growth factor 1 and insulin-like growth factor binding proteins on outcomes in acute myeloid leukemia

References

• Altman JK, Platanias LC. Acute myeloid leukemia: potential for new therapeutic approaches targeting mRNA translation pathways. Int J Hematol Oncol 2013;2(3). doi: 10.2217/ijh.13.23.
   PubMedGoogle Scholar
• Dinner SN, Giles FJ, Altman JK. New strategies for relapsed acute myeloid leukemia: fertile ground for translational research. Curr Opin Hematol 2014;21:79–86.
   PubMed Web of Science ®Google Scholar
• Gutierrez SE, Romero-Oliva FA. Epigenetic changes: a common theme in acute myelogenous leukemogenesis. J Hematol Oncol 2013;6:57.
   PubMed Web of Science ®Google Scholar
• Kosan C, Ginter T, Heinzel T, et al. STAT5 acetylation: mechanisms and consequences for immunological control and leukemogenesis. JAKSTAT 2014;2:e26102.
   Google Scholar
• Kupsa T, Horacek JM, Jebavy L. The role of cytokines in acute myeloid leukemia: a systematic review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2013;156:291–301.
   Web of Science ®Google Scholar
• Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008;8:915–928.
   PubMed Web of Science ®Google Scholar
• Douglas JB, Silverman DT, Pollak MN, et al. Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 molar ratio and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 2010;19:2298–2306.
   PubMed Web of Science ®Google Scholar
• Khandwala HM, McCutcheon IE, Flyvbjerg A, et al. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000;21:215–244.
   PubMed Web of Science ®Google Scholar
• Ariga M, Nedachi T, Akahori M, et al. Signalling pathways of insulin-like growth factor-I that are augmented by cAMP in FRTL-5 cells. Biochem J 2000;348:409–416.
   PubMed Web of Science ®Google Scholar
• Chapuis N, Tamburini J, Cornillet-Lefebvre P, et al. Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody. Haematologica 2010;95:415–423.
   PubMed Web of Science ®Google Scholar
• Doepfner KT, Spertini O, Arcaro A. Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway. Leukemia 2007;21:1921–1930.
   PubMed Web of Science ®Google Scholar
• Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002;23:824–854.
   PubMed Web of Science ®Google Scholar
• Migita T, Narita T, Asaka R, et al. Role of insulin-like growth factor binding protein 2 in lung adenocarcinoma: IGF-independent antiapoptotic effect via caspase-3. Am J Pathol 2010;176:1756–1766.
   PubMed Web of Science ®Google Scholar
• Fidler MJ, Basu S, Buckingham L, et al. Insulin-like growth factor receptor 1 (IGFR-1) and outcome measures in advanced non-small cell lung cancer (NSCLC) patients treated with gefitinib. J Clin Oncol 2008;26(15 Suppl.):Abstract 8036.
   Web of Science ®Google Scholar
• Fidler MJ, Shersher DD, Borgia JA, et al. Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls. Ther Adv Med Oncol 2012;4:51–60.
   PubMed Web of Science ®Google Scholar
• Shersher DD, Vercillo MS, Fhied C, et al. Biomarkers of the insulin-like growth factor pathway predict progression and outcome in lung cancer. Ann Thorac Surg 2011;92:1805–1811; discussion 1811.
   PubMed Web of Science ®Google Scholar
• Gualberto A, Hixon ML, Karp DD, et al. Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. Br J Cancer 2011;104:68–74.
   PubMed Web of Science ®Google Scholar
• Hizuka N, Sukegawa I, Takano K, et al. Characterization of insulin-like growth factor I receptors on human erythroleukemia cell line (K-562 cells). Endocrinol Jpn 1987;34:81–88.
   PubMedGoogle Scholar
• Neri LM, Borgatti P, Tazzari PL, et al. The phosphoinositide 3-kinase/AKT1 pathway involvement in drug and all-trans-retinoic acid resistance of leukemia cells. Mol Cancer Res 2003;1:234–246.
   PubMed Web of Science ®Google Scholar
• Abe S, Funato T, Takahashi S, et al. Increased expression of insulin-like growth factor i is associated with Ara-C resistance in leukemia. Tohoku J Exp Med 2006;209:217–228.
   PubMed Web of Science ®Google Scholar
• Dawczynski K, Kauf E, Schlenvoigt D, et al. Elevated serum insulin-like growth factor binding protein-2 is associated with a high relapse risk after hematopoietic stem cell transplantation in childhood AML. Bone Marrow Transplant 2006;37:589–594.
   PubMed Web of Science ®Google Scholar
• Dawczynski K, Kauf E, Zintl F. Changes of serum growth factors (IGF-I,-II and IGFBP-2,-3) prior to and after stem cell transplantation in children with acute leukemia. Bone Marrow Transplant 2003;32: 411–415.
   PubMed Web of Science ®Google Scholar
• Larsson SC, & Wolk A. Overweight and obesity and incidence of leukemia: a meta-analysis of cohort studies. International Journal of Cancer. 2008; 122(6): 1418–21. doi:10.1002/ijc.23176.
   PubMed Web of Science ®Google Scholar
• Gallagher EJ, DeRoith D. Diabetes, antihyperglycemic medications and cancer risk: smoke or fire? Curr Opin Endocrinol Diabetes Obes 2013; 20:485–494.
   PubMed Web of Science ®Google Scholar
• Nagel G, Stocks T, Späth D, Hjartåker A, Lindkvist B, Hallmans G, et al. Metabolic factors and blood cancers among 578,000 adults in the metabolic syndrome and cancer project (Me-Can). Annals of Hematology, 2012;91: 1519–31
   PubMed Web of Science ®Google Scholar
• Calle EE, Rodriguez C, Walker-thurmond K, & Thun MJ. Overweight, obesisty, and mortality from cancer in a Prospectively Studied Cohort of U.S. Adults. NEJM 2003;1625–1638.
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453–474.
   PubMed Web of Science ®Google Scholar